Sodium Thiosulfate in Acute Myocardial Infarction:: A Randomized Clinical Trial
Publication date
2023
Authors
de Koning, Marie-Sophie Ly
van Dorp, Paulien
Assa, Solmaz
Pundziute-Do Prado, Gabija
Voskuil, Michiel
Anthonio, Rutger L
Veen, D.
Leiner, Tim
Sibeijn-Kuiper, Anita J.
van Goor, Harry
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
In this proof-of-principle trial, the hypothesis was investigated that sodium thiosulfate (STS), a potent antioxidant and hydrogen sulfide donor, reduces reperfusion injury. A total of 373 patients presenting with a first ST-segment elevation myocardial infarction received either 12.5 g STS intravenously or matching placebo at arrival at the hospital and 6 hours later. The primary outcome, infarct size, measured by cardiac magnetic resonance at 4 months after randomization, did not differ between the treatment arms. Secondary outcomes were comparable as well, suggesting no clinical benefit of STS in this population at relatively low risk for large infarction.
Keywords
clinical trial, hydrogen sulfide, ischemia-reperfusion injury, myocardial infarction, randomized controlled trial, thiosulfates
Citation
de Koning, M-S L, van Dorp, P, Assa, S, Pundziute-Do Prado, G, Voskuil, M, Anthonio, R L, Veen, D, Leiner, T, Sibeijn-Kuiper, A J, van Goor, H, van Veldhuisen, D J, van der Meer, P, Nijveldt, R, Lipsic, E & van der Harst, P 2023, 'Sodium Thiosulfate in Acute Myocardial Infarction: A Randomized Clinical Trial', JACC: Basic to Translational Science, vol. 8, no. 10, pp. 1285-1294. https://doi.org/10.1016/j.jacbts.2023.06.001